Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

Ítems similars

• A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia
  per: Farlow, Martin R., et al.
  Publicat: (2013)
• Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer’s disease
  per: Micca, Joseph L, et al.
  Publicat: (2014)
• Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24‐week, Randomized, Double‐Blind Parallel‐Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily)
  per: Zhang, Zhen‐Xin, et al.
  Publicat: (2016)
• Evaluating Response to High‐Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease
  per: Farlow, Martin R., et al.
  Publicat: (2015)
• A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors
  per: Diaz, Maria Cristina B., et al.
  Publicat: (2015)